Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5398_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •Preface
- •Contents
- •Contributors
- •1. Introduction
- •2. The Initial Phase of Drug Delivery Systems
- •3. Recent Drug Delivery Systems
- •4. Drug Delivery via Carriers
- •5.4 Polymer-Lipid Hybrid Nanoparticles Drug Delivery System
- •5.5 Self-Micro Emulsifying Drug Delivery System
- •5.6 In Situ Gel Drug Delivery System
- •5.8 Targeted Drug Delivery
- •6. Ceramic-Based Drug Delivery System
- •7. Polysaccharide-Based Drug Delivery System
- •8. Closed Loop Insulin Delivery System
- •9. Liposome-Mediated Drug Delivery
- •5. Recent Drug Delivery Systems
- •5.3 Hexagonal Boron Nitride Nanosheet Drug Delivery System
- •10. Dendrimers
- •11. PEGylated Drug Delivery System
- •12. Antibody-Drug Conjugate System
- •13. Mesoporous Silica-Based Drug Delivery
- •14. Transdermal Drug Delivery System
- •15. Hydrogel-Mediated Ocular Drug Delivery
- •16. Challenges with Current Drug Delivery Systems
- •17. Future Direction and Conclusion
- •References
- •1. Introduction
- •2. Pharmacokinetic Principles
- •2.1 Application of the Pharmacokinetic Principle in the Biomedical Fields
- •3. Cell Membrane/Biological Membrane
- •3.1 Passage of Drugs Across Biological Membranes
- •3.1.1 Simple Transport
- •3.1.2 Specialized Transport
- •4. Routes of Drug Administration
- •4.1 Oral (Enteral) Versus Parenteral Administration
- •4.2 Various Routes of Drug Administration
- •5. Absorption
- •5.1 Factors Affecting Absorption of Drugs
- •5.1.1 Physio-chemical Characteristics
- •5.1.2 Dosage Form
- •5.1.3 Concentration and Volume
- •5.1.4 Blood Flow
- •5.1.5 Surface Area
- •5.1.6 Administration Route
- •5.1.7 Disease States
- •5.2 Gastrointestinal Tract
- •5.3 Parenteral Sites
- •5.4 Pulmonary Sites (Alveoli)
- •5.5 Topical Sites
- •6. Distribution
- •6.1 Factors Affecting Distribution of Drugs
- •6.1.1 Physicochemical Properties of the Drug
- •6.1.2 Binding to Plasma and Tissue Proteins
- •6.1.3 Blood Flow and Organ Size
- •6.1.4 Specialized Compartments and Barriers
- •6.1.5 Specialized Transport Systems
- •6.1.6 Disease States
- •6.1.7 Physiological Factors
- •7. Metabolism/Biotransformation
- •7.1 Functions of Metabolism
- •7.2 Sites of Metabolism
- •7.3.1 Microsomal Enzymes
- •7.3.2 Non-microsomal Enzymes
- •7.4 Pathways of Biotransformation
- •8. Excretion
- •8.1 Routes of Excretion
- •8.1.1 Renal Excretion of Drugs
- •8.1.2 Extra-Renal Excretion of Drugs
- •9.1 Minimum Effective Concentration (MEC)
- •9.2 Maximum Safe Concentration (MSC) or Minimum Toxic Concentration (MTC)
- •9.4 Area Under the Curve (AUC)
- •9.5 Peak Effect
- •9.7 Onset of Action
- •9.8 Onset Time
- •9.9 Duration of Action
- •10. Order of Pharmacokinetic Processes
- •10.1 Zero-Order Kinetics
- •10.2 First-Order Kinetics
- •10.3 Mixed-Order Kinetics
- •11. Pharmacokinetic Models
- •11.1 Compartmental Models
- •11.3 Physiological Models
- •12. Determinants of Pharmacokinetics
- •12.1 Absorption
- •12.1.1 Bioavailability
- •12.1.2 Bioequivalence
- •12.1.3 Area Under Curve (AUC)
- •12.2 Distribution
- •12.2.1 Volume of Distribution
- •12.3 Elimination
- •12.3.2 Clearance (Cl) or Body Clearance
- •13. Conclusion
- •References
- •1. Introduction
- •2. Principles of Targeted Drug Delivery
- •3.1 Changes in pH and Salt Development
- •3.7 Dendrimers
- •4.1 Small-Sized Molecule-Based Targeting Strategies
- •4.2 Nucleic Acid Fragment-Based Targeting Strategies
- •4.3 Peptide- and Antibody-Based Targeting Strategies
- •4.4 Cell-Based Targeting Strategies
- •5. Conclusion
- •References
- •3.4 Liposomes
- •3.5 Solid Lipid Nanoparticles
- •3.6 Co-crystal Preparation
- •1. Introduction
- •2. History
- •3.1 Organic Nanoparticles
- •3.2 Inorganic Nanoparticles
- •4. Nanotechnology-Based Drug Delivery Systems
- •4.1 Smart Drug Delivery Systems
- •4.3 Multifunctional Drug Carriers
- •4.4 Organic/Inorganic Composites
- •5. Nanoparticulate Drug Delivery Systems
- •5.1 Liposomes
- •5.2 Microemulsions
- •5.3 Nanoparticles
- •6. Applications
- •6.1 Enhanced Drug Delivery
- •6.2 Overcoming Biological Barriers
- •6.3 Controlled Drug Release
- •6.4 Combination Therapy
- •6.5 Personalized Medicine
- •7. Limitations
- •7.1 Complexity and Cost
- •7.2 Biocompatibility and Toxicity
- •7.3 Stability and Shelf Life
- •7.4 Drug Loading and Release
- •7.5 Biological Barriers and Clearance
- •8. Conclusions
- •References
- •1. Introduction
- •2. Guidelines for Design of Lipid-Based Formulations
- •3. Formulation Strategies
- •3.1 Lipid Nanoparticles
- •3.1.1 Solid Lipid Nanoparticles (SLNs)
- •3.1.2 Nanostructured Lipid Carriers (NLCs)
- •3.2 Liposomes
- •3.2.1 Conventional Liposomes
- •3.2.2 PEGylated Liposomes
- •3.2.3 Multifunctional Liposomes
- •3.3 Microemulsions and Self-micro Emulsifying Drug Delivery Systems (SMEDDS)
- •3.4 Hybrid Systems
- •3.4.1 Lipid-Polymer Hybrid Nanoparticles
- •3.4.2 Lipid-Protein Hybrid Systems
- •4. Advanced Characterization Methods
- •4.1 In Vitro and In Vivo Assessment
- •4.1.1 Dissolution Studies
- •4.1.2 Permeability Studies
- •4.2 Imaging Techniques
- •4.2.1 Electron Microscopy
- •4.2.2 Fluorescence Imaging
- •Fluorescent Probes
- •Confocal Microscopy
- •4.2.3 Magnetic Resonance Imaging (MRI)
- •4.3 Stability Studies
- •4.3.1 Oxidative Stability
- •4.3.2 Thermal Stability
- •5. Applications of Lipid-Based Drug Delivery Systems
- •5.1 Cancer Therapy
- •5.1.1 Targeted Drug Delivery
- •5.1.2 Combination Therapy
- •5.2 Central Nervous System Disorders
- •5.2.2 Neuroprotective Effects
- •5.3 Antiviral and Antimicrobial Applications
- •5.3.1 Lipid Nanoparticles for Antiviral Drugs
- •5.3.2 Antibiotic Delivery Systems
- •6. Future Perspectives and Challenges
- •7. Conclusion
- •References
- •1. Introduction
- •3. Design and Characterization of Polymeric Drug Delivery Systems
- •4. Responsive Polymers
- •4.1 Polymeric Hydrogels
- •4.1.1 Characterization of Polymeric Hydrogels
- •Structural Analysis
- •Functional Analysis
- •4.2 Polymeric Micelles
- •4.2.1 Characterization of Polymeric Micelle
- •Critical Micelle Concentration Determination (CMC)
- •Morphological Characterization
- •Physicochemical Characterization
- •4.3 Liposomes
- •4.3.1 Ethosome
- •4.3.2 Transferosome
- •4.3.3 Niosome
- •4.4 Polyplexes or Polymer-Drug Conjugates
- •4.4.1 Dendrimers
- •4.4.2 Polymer-Protein Conjugates
- •4.4.3 Polymeric Nanoparticles
- •5. Conclusion
- •6. Future Prospects
- •References
- •1. Introduction
- •2.1 Types of Stimuli
- •3. Mechanism of Stimuli Responsiveness
- •3.1 pH-Responsive Systems
- •4. Materials
- •4.1 pH-Responsive Materials
- •4.4 Synthetic Thermo-Responsive Materials
- •4.7 Magnetic Responsive Materials
- •4.8.1 Intrinsically Conducting Polymers
- •4.8.2 Hydrogels
- •5. Methods
- •5.1 pH-Responsive Drug Delivery Systems
- •6. Conclusion
- •7. Notes
- •References
- •1. Introduction
- •3. Basic Features Required for the Biomaterial
- •4. Characteristics of Biomaterials
- •6. Biocompatibility as the Crucial Item
- •7. Biomaterials in Drug Delivery
- •8. Controlled Drug Delivery
- •9. Clinical Need for Controlled Drug Delivery
- •10. Biomaterials for Controlled Release of Small Molecules
- •11. Bioresponsive Polymers: From Design to Implementation
- •11.3 Hydrolysis and Enzymatically Responsive Polymers
- •11.7 Swelling and Contracting Polymers
- •12. Transdermal Drug Delivery Systems
- •12.1 Barriers to Transdermal Delivery
- •12.2 Development of Transdermal Drug Delivery Patches
- •12.3 Hydrogels Versus Non-hydrogel Polymeric Patches
- •12.4 Patches Based on Biopolymers
- •12.5 Patches Based on Synthetic Polymers
- •12.6 Drug Particles/Carriers
- •12.7 Commercial Patches
- •13. Smart Biomaterials
- •14. Conclusion and Future Perspective
- •References
- •1. Introduction
- •1.1 Historical Evolution
- •2. Skin Anatomy and Physiology
- •2.1 Cutaneous Layer Organization
- •2.2 Cutaneous Barrier Function
- •3. Mechanisms of Transdermal Drug Delivery
- •4. Formulation Strategies for Transdermal Drug Delivery
- •4.1 Drug Selection Criteria
- •4.2 Vehicle and Excipient Considerations
- •4.3 Permeation Enhancers
- •4.4 Transdermal Drug Delivery Technologies
- •5. Evaluation Methods for Transdermal Drug Delivery Systems
- •6. Applications of Transdermal Drug Delivery
- •6.1 Therapeutic Areas
- •6.2 Case Studies of Successful Transdermal Products
- •7. Regulatory Considerations and Approval Process
- •7.1 FDA Guidelines for Transdermal Drug Delivery Systems
- •7.2 Quality Control and Manufacturing Standards
- •7.3 Clinical Trial Requirements
- •8. Challenges and Future Perspectives
- •8.1 Overcoming Cutaneous Barrier Properties
- •8.2 Expanding the Range of Deliverable Drugs
- •8.3 Intelligent and Responsive Transdermal Systems
- •8.4 Integration with Other Drug Delivery Technologies
- •8.5 Conclusion
- •References
- •1. Background
- •2. Importance of the Tumor Microenvironment (TME) in Cancer Progression and Therapy
- •2.1 Components of the TME
- •2.2 Therapeutic Targeting of the TME
- •2.3 Impact of Standard Therapies on the TME
- •3. Tumor-Homing Peptides
- •3.1 Different Strategies for Targeting Peptides to Tumor Microenvironment
- •3.2 Applications and Development
- •3.3 Examples and Discoveries
- •4. Tumor Microenvironment Responsive Drug Delivery Systems (DDSS)
- •5. Nanoparticle-Based Smart Drug Delivery Systems
- •5.1.1 Endogenous Stimulus-Responsive Drug Delivery Systems (DDSs)
- •5.1.2 Exogenous Stimulus-Responsive DDSs
- •5.2.2 Dynamic Strategies for Tumor Targeting
- •6. Challenges and Opportunities for Targeted Delivery to Cancer Cells
- •7. Future Directions
- •8. Conclusions
- •References
- •1. Introduction
- •2. Materials
- •2.1 Types of Biosensors
- •2.1.2 Smart Polymers
- •2.1.3 Microfabricated Devices
- •2.2.1 Enzyme-Based Biosensors
- •2.2.2 Antibody-Based Biosensors
- •2.2.3 Aptamer-Based Biosensors
- •2.2.4 Whole-Cell-Based Biosensors
- •3. Methods
- •3.1 Approach Toward Designing Biosensors
- •3.1.1 Selection of the Analyte and Bioreceptors
- •3.1.2 Immobilization of Biosensors
- •3.1.3 Selection of Transducer
- •3.2 Green Biosensors
- •3.3 Challenges in Development of Biosensors-Based Drug Delivery Systems
- •References
- •1. Introduction
- •3. Ocular Barriers Hindering Absorption of Drugs
- •3.1 Precorneal Barriers
- •3.1.1 Tear Film, Tear Turnover, and Nasolacrimal Duct Drainage
- •3.1.3 Conjunctival and Scleral Barriers
- •3.2 Corneal Barrier
- •3.3 Blood-Ocular Barriers
- •4. Various Routes for Ocular Drug Delivery
- •4.1 Topical Administration
- •4.2 Subconjunctival Administration
- •4.3 Transscleral Administration
- •4.4 Intracameral Administration
- •4.5 Intravitreal Injections/Implants (IVIs)
- •4.6 Retrobulbar Administration
- •4.7 Systemic Administration
- •5. Nanotechnology-Based Ocular Drug Delivery Platforms
- •5.1 Nanoparticles (NPs)
- •5.1.1 Polymeric Nanoparticles (PNPs)
- •5.2 Nanomicelles
- •5.3 Nanoemulsions (NEs)
- •5.4 Nanosuspensions
- •5.5 Nanocrystals (NCs)
- •5.6 Liposomes
- •5.7 Microemulsions
- •5.8 Niosomes
- •5.10 Dendrimers
- •5.11 Nanowafers
- •5.12 Cubosomes
- •5.13 Bilosomes
- •5.14 Olaminosomes
- •5.15 Contact Lenses
- •5.16 Hydrogels
- •5.17 Microneedles (MNs)
- •6. Alternative Ocular Drug Delivery Approaches
- •6.1 Gene Therapy
- •6.1.1 Viral Vectors
- •6.1.2 Non-viral Vectors
- •6.1.3 Antisense Oligonucleotides (ASOs), RNAi, CRISPR-Cas9
- •6.2 Exosomes
- •6.3 Self-nano Emulsifying Drug Delivery Structures (SNEDDS)
- •7. Clinical Status of Nanotechnology-Based Ocular Drug Delivery Systems
- •8. Future Outlooks
- •References
- •1. Introduction
- •2. Anatomy and Physiology of GIT
- •2.1 Mouth and Esophagus
- •2.2 Stomach
- •2.3 Small Intestine
- •2.4 Ruminant Digestive System
- •3. Blood Supply
- •4. Nerve Supply
- •5. Challenges in GIT Drug Delivery
- •5.1 Acidic Environment of the Stomach
- •5.2 Alkaline pH of the Intestine
- •5.3 Variable GI Transit Times
- •6. Future Opportunities in GIT Drug Delivery
- •6.1.1 Targeted Delivery Systems
- •6.1.2 Ligand-Conjugated Nanoparticles
- •6.1.3 Liposomes
- •6.1.4 Solid Lipid Nanoparticles
- •6.2 Controlled Release Systems
- •6.2.1 Osmotic Pumps
- •6.2.2 Matrix Systems
- •6.3 Mucoadhesive Systems
- •6.3.1 Mucoadhesive Polymers
- •6.4 Absorption Enhancers
- •6.5 Tight Junction Modulators
- •6.6 Development of Prodrugs
- •7. Conclusion
- •References
- •1. Introduction
- •2. Anatomy and Physiology of the Respiratory System
- •3. Traditional Methods of Respiratory Drug Delivery
- •3.1 Metered-Dose Inhalers (MDIs)
- •3.2 Dry Powder Inhalers (DPIs)
- •3.3 Nebulizers
- •3.5 Improved Patient Compliance Through User-Friendly Devices
- •3.8 Enhanced Absorption by Overcoming Biological Barriers
- •3.9 Macromolecule Delivery Facilitation
- •3.10 Reduced Side Effects Through Improved Targeting
- •3.11 Formulation Challenges Addressed
- •3.12 Smart Technology Integration for Personalized Treatment
- •3.13 Environmental Sustainability Considerations
- •4. Novel Drug Delivery Approaches
- •4.2 Liposomal Formulations
- •5. Advanced Inhalation Devices
- •6. Targeted Drug Delivery Strategies
- •6.2 pH-Responsive Drug Release
- •7. Emerging Therapeutics for Respiratory Diseases
- •8.2 Combination Therapies
- •8.3 Prodrug Approaches
- •9. Personalized Medicine in Respiratory Drug Delivery
- •10. Future Perspectives and Emerging Technologies
- •10.1 3D-Printed Inhalers
- •11. Conclusion
- •References
- •1. Introduction
- •2. Delivery of Small Molecules
- •3. Drawbacks of Conventional Drug Delivery System
- •4. Factors Affecting Cardiovascular Drug Targeting System
- •4.1 Particle Shape
- •4.2 Particle Size
- •4.3 Particle Density
- •4.4 Flow Characteristics
- •5. Various Targeted Drug Delivery Systems
- •5.1 Application of Exosomes and EVs (Extracellular Vesicles)
- •5.4 Nanomedicines in Cardiovascular Therapy
- •5.5 PLGA-Based Nanoparticles
- •5.6 Liposomal Delivery Systems
- •5.7 Delivery of Biologicals
- •5.8 RNA-Based Delivery
- •5.9 Therapeutic Proteins and Peptides
- •6. Future Perspectives and Challenges
- •7. Conclusion
- •References
- •1. Introduction
- •2. Materials
- •2.1 Equipment
- •2.2 Drugs
- •3. Methods
- •3.1.1 Extrusion-Based 3D Bioprinting
- •3.1.2 Inkjet 3D Bioprinting
- •3.1.3 Light-Based Bioprinting
- •3.1.4 Laser-Assisted Printing
- •3.2 Multiple Drug Delivery
- •3.2.1 Multilayer Films with Capsule-Integrated Polypeptide/Polyelectrolyte
- •3.2.2 Multilayer Shells Using Polypeptides/Polyelectrolytes (PL or PG) and LbL Assembly
- •3.3.1 Physical Stimulation-Responsive Drug Delivery Systems
- •3.3.4 Light-Responsive Drug Delivery Systems (LRDDS)
- •3.4 Small Molecule Delivery System
- •3.4.1 Intraarticular Delivery System
- •3.5 Gene Delivery System
- •3.6 Stem Cell Technology
- •4. Conclusion
- •References
- •1. Introduction
- •2. Importance of Targeted Drug Delivery to the Reproductive System
- •3. Challenges in Drug Delivery to the Reproductive System
- •4. Advances in Drug Delivery Systems
- •4.2 Liposomes
- •4.3 Hydrogels and Biodegradable Polymers
- •4.4 Injectable and Implantable Devices
- •4.5 Micro- and Nano-Needles
- •4.6 Spermbots
- •5.1 Vaginal and Cervical Delivery
- •5.2 Uterine and Intrauterine Delivery
- •5.3 Penile and Testicular Delivery
- •6. Targeted and Precision Medicine Approaches
- •6.1 Hormone Replacement Therapy (HRT)
- •6.2 Gene Therapy and RNA-Based Approaches
- •6.3 Personalized Medicine in Reproductive Disorders
- •7. Therapeutic Applications and Innovations
- •7.1 Infertility and Assisted Reproductive Technologies (ART)
- •7.2 Treatment of Reproductive Cancers
- •7.4 Contraceptive Technologies
- •8. Safety and Regulatory Considerations
- •9. Future Directions and Emerging Trends
- •References
- •1. Introduction
- •2. Liposomes
- •3. Preparation of Liposomes
- •3.1 Reagents
- •3.2 Hydration and Liposome Extrusion
- •3.4 Conjugation
- •3.8 PEGylation
- •3.8.1 Materials Required
- •3.8.2 Procedure
- •3.9 Liposomal Doxorubicin (LD)
- •3.10 Marqibo (Vincristine Sulfate)
- •3.11 DepoCyt (Cytarabine)
- •4. Poly(Lactic-co-Glycolic Acid, PLGA) Nanoparticles
- •4.2 Methods
- •4.2.1 Reagents
- •4.2.2 Procedure
- •5. Polycaprolactone (PCL)
- •5.2 pH Sensitivity and Stability
- •5.3 Methods
- •5.3.1 Materials
- •5.4 Drug Loading
- •6. Chitosan-Based Systems
- •6.1 Encapsulation of Nucleic Acids and Proteins
- •6.3 pH Sensitivity and Stability of Chitosan Nanoparticles
- •6.4 Methodology
- •6.4.1 Reagents
- •6.4.2 Procedure
- •7. Dendrimers
- •7.1 Antisense Oligonucleotides
- •7.2 Small-Interfering RNA (siRNA)
- •7.4.1 Divergent Method
- •7.4.2 Convergent Method
- •8. Challenges in Developing Orphan Drugs
- •References
- •1. Introduction
- •2. Vaccine Delivery Systems
- •3. Polymers
- •4. Non-biodegradable NPs
- •5. Calcium Phosphate NPs
- •6. Colloidally Stable Nanoparticles
- •7. Proteasomes
- •8. Liposomes
- •9. Virus-like Particles (VLPs) and Virosomes
- •10. Immune-Stimulating Complexes ISCOMs
- •11. Emulsion Delivery Systems
- •12. Exosome-Based Vaccine Delivery System
- •13. Immunotherapy Using Nano- and Microparticles
- •14. Properties and Role of Nanoparticles in Drug Delivery
- •15. Biomimicry
- •16. Micellar Systems
- •17. Hydrogels
- •18. Edible Vaccines
- •19. Plant-Derived Viruses
- •20. Melt-in Mouth Strips
- •21. Transdermal Delivery
- •22. Delivery of Nucleic Acids
- •23. mRNA Delivery
- •24. Delivery of Cytokines
- •25. DC Targeting
- •26. Drug Delivery Targeting T Cells
- •27. Conclusions
- •References
- •1. Introduction
- •2. Materials
- •2.1 Equipment
- •2.2 Reagents and Solutions
- •3. Methods
- •3.1 Adenovirus
- •3.3 Retroviral Vectors (RV)
- •3.4 Lentivirus (LV)
- •4. Conclusion
- •References
- •1. Introduction
- •2. Technologies Utilizing Cells in Treating Diseases
- •2.1 Somatic Cell Technologies
- •2.2 Immortalized Cell Lines
- •2.5 Genome Editing Technologies
- •2.6 Cell Plasticity Technologies
- •3. Different Kinds of Cells Are Utilized in the Process of Cell Treatment
- •4. The Practices of Regenerative Medicine and Cell Therapy
- •4.1 Veterinary Medicine Therapeutic Uses
- •5. Advancements and Challenges in Drug Delivery
- •6. Drug Delivery Systems and Applications
- •6.2 Drug Nanocarriers Based on Hyaluronic Acid
- •6.3 Hexagonal Boron Nitride Nanosheet Drug Delivery System
- •6.4 Polymer-Lipid Hybrid Nanoparticles
- •6.6 In Situ Gel Drug Delivery System

Stimuli-Responsive Drug Delivery Systems: From Concept to Clinical Translation 149
different wavelengths of light, have been extensively studied as
light-responsive groups [
99]. To disassemble catanionic vesicles,
the azobenzene moiety’s configuration has been changed
[99, 100]. A light-responsive catanionic self-assembly system (multilamellar and unilamellar vesicles) was created from sodium dodecyl sulfate (SDS) and 4-cholesterocarbonyl-4′-(N,N,Ntriethylamine butyloxyl bromide) azobenzene (CAB). Rhodamine
B and doxorubicin were released from the vesicles as a result of
reversible isomerization of CAB under UV light exposure, which
increased the interlamellar spacing.
To release medication without photolysis, another tactic is to
alter hydrophilicity. For instance, photooxidation serves as the basis
for the release mechanism in unsaturated phospholipids. When
unsaturated phospholipids are oxidized using singlet oxygen,
their hydrophobicity is decreased, which causes instability and
increases the permeability of the liposomes [
101, 102]. Lovell
et al. utilized the unsaturated phospholipid dioleoylphosphatidylcholine (DOPC) for the controlled release of doxorubicin loaded in
porphyrin-phospholipid (PoP) liposomes under NIR [
103]. PoP,
acting as the photosensitizer, generated active singlet oxygen,
which led to an acceleration of DOX release when exposed to
light at 665 nm. Singlet oxygen was confirmed to be involved in
the mechanism by the inhibition of drug release in the presence of
an oxygen scavenger or antioxidant.
5.6 ElectroResponsive Drug
Delivery Systems
In the electro-responsive gel erosion mechanism, polyelectrolyte
gels can be disintegrated in the presence of an electric field. These
gels are made up of two water-soluble polymers that combine to
form a hydrogel through ionic or hydrogen bond interactions. The
formation of these materials is depended on pH of the environment. For instance, a polyallylamine and heparin complex can form
over a pH range of 3–10, but it breaks down at pH 11
104]. Hydrogen bonds in the polyelectrolyte gel are broken by
[
hydroxyl ions produced during the electrolysis of water when a
cathode is positioned near it and an anode is positioned away
from it [
105]
he loaded drug is released as a result of the polymer
. T
complex eroding.
Hydrogels generally
have low poor conductivity, which hinders
their performance as electro-responsive drug delivery systems
(ESDSs). In order to improve the electrical conductivity of these
hydrogels, conductive substances like graphene-based nanomaterials, conducting polymers, and carbon nanotubes can be mixed into
the polymer gel. Both single-walled and multi-walled carbon nanotubes have been mostly used to enhance the mechanical strength
and electrical properties of hydrogels [
106, 107].
For instance,
Yang et al. created conductive polypyrrole-reinforced hyaluronic
acid hydrogels, which improved their electrical conductivity and
biocompatibility for use in biomedical applications

150 Manisha et al.
[108]. Moreover, to enhance the functionality of an electroresponsive delivery system, reduced graphene oxide (rGO) has been composited with polyethylene glycol diglycidyl ether and Jeffamine
polyetheramine [
109]. When rGO is present, the electrostatic
repulsion increases at a negative applied potential, hastening the
release of the drug from the composite.
5.7 EnzymeResponsive Drug
Delivery Systems
6 Conclusion
Enzyme-responsive polymeric nanoparticles have been created for
the treatment of diseases such as diabetes and cancer. For example,
4-hydroxymandelic acid was utilized as the framework to construct
enzyme-responsive linkers [
110]. The drug and enzyme substrates
were attached to the hydroxyl groups in the mandelate core. An
enzyme found in the infected cells caused the linker to break,
releasing the conjugated drug spontaneously. The work of Wong
et al. provides another illustration of enzyme-responsive DDS utilizing polymeric nanoparticles [
111]. Liposomes have garnered
significant interest as superior drug delivery vehicles due to their
numerous benefits, such as their large surface areas, appropriate
sizes, and distinct chemical characteristics. By conjugating with
targeting ligands that interact with receptors on the surface of the
treated cell, liposomes can either passively or actively accumulate in
target tissues. For example, Wan et al. reported a matrix metalloproteinase (MMPs)-responsive liposomal formulation for gene
delivery. An MMP-cleavable peptide was used as the linker to
functionalize PEG chains into anionic liposomes containing
adenovirus [
112].
Recent studies on the differences between pathological areas,
including tumors, and normal areas have observed that pathological regions exhibit abnormal conditions such as changes in pH,
temperature, and redox states, along with the downregulation or
overexpression of certain receptors and transporters. These significant alterations provide novel opportunities for creating smart drug
delivery systems (DDS) that are stimuli-responsive. Medications
can be put into specialized car riers that react to external stimuli
such as magnetic and electric fields or to the abnormal conditions of
pathological areas. The smart carriers have the ability to change
physically and chemically in response to these stimuli, which can
lead to the controlled and selective release of the drug payload. To
avoid or reduce unintended off-target effects on non-target tissues,
a deeper comprehension of the stimuli sensitivity of these designed
DDS is still required. One of the upcoming challenges in the
development of new DDS is creating systems that can react to
particular biomarkers at extremely low concentrations. Future challenges in developing new DDS include investigation of cutting-

7 Notes
Stimuli-Responsive Drug Delivery Systems: From Concept to Clinical Translation 151
edge nanotechnology-based personalized medicine techniques,
combination therapies, and new stimuli. Additionally, the design
and development of multifunctional DDS for simultaneous diagnosis and therapy of diseases will be another important approach.
Improve the biocompatibility, stability, and specificity of systems
that respond to stimuli in order to make them more suitable for
clinical use.
1. Definition: Stimuli-responsive drug delivery systems are
synthesized to release therapeutic drugs in response to specific
physiological triggers or stimuli.
2. Types of Stimuli: Common stimuli include pH changes, redox,
temperature variations, enzymatic activity, light exposure, and
magnetic fields.
3. pH-Responsive Systems: Modify the release of drugs according
to changes in pH in various body compartments, such as the
acidic environment found in tumors.
4. Temperature-Responsive Systems: Modify drug release based
on temperature changes; this is helpful for targeted therapy in
the treatment of hyperthermia.
5. Enzyme-Responsive Systems: Releasing medication in reaction
to the enzymatic activity found in pathological states, like
cancerous tissues.
6. Light-Responsive Systems: Drug release can be triggered by
light exposure by using light-responsive molecules such as
azobenzenes or nitrobenzyl groups.
7. Magnetic-Responsive Systems: Under the effect of an external
magnetic field, use magnetic nanoparticles to direct and release
medications in particular tissues.
8. Redox-Responsive Systems: Make use of redox-responsive
bonds, like disulfide linkages, to cause drug release in reaction
to the intracellular environment that is reductive.
9. Electrically Responsive Systems: To enable controlled drug
release, use materials that react electrochemically or change in
conductivity when exposed to electric fields.
10. Advantages: Target drug release to diseased tissues or organs
specifically to increase drug efficacy and decrease side effects.
11. Materials Used:
properties in response to stimuli include metals, polymers,
lipids, and hybrid materials.
Substances that change their physicochemical

152 Manisha et al.
References
12. Controlled Release Mechanisms: Involve stimuli-induced
reversible changes in material structure, such as conformational
changes or degradation.
13. Current Research Trends: Improve the biocompatibility, stability, and specificity of systems that respond to stimuli in order
to make them more suitable for clinical use.
14. Challenges: One of the upcoming challenges in the development of new DDS is creating systems that can react to particular biomarkers at extremely low concentrations.
15. Future Directions: investigation of cutting-edge nanotechnology-based personalized medicine techniques, combination
therapies, and new stimuli.
1. Adepu S, Ramakrishna S (2021) Controlled
drug delivery systems: current status and
future directions. Molecules (Basel, Switzerland) 26(19):5905
2. Kallepalli B, Garg U, Jain N, Nagpal R,
Malhotra S, Tiwari T, Kaul S, Nagaich U
(2024) Intelligent drug delivery: pioneering
stimuli-responsive systems to revolutionize
disease management- an in-depth exploration. Curr Drug Deliv.
2174/0115672018278641231221051359.
Advance online publication
3. Zhang M, Hu W, Cai C, Wu Y, Li J, Dong S
(2022) Advanced application of stimuliresponsive drug delivery system for inflammatory arthritis treatment. Mater Today Bio 14:
100223
4. Yerushalmi R, Scherz A, Van Der Boom ME,
Kraatz H-B (2005) Stimuli responsive materials: new avenues toward smart organic
devices. J Mater Chem 15:4480–4487
5. Kocak G, Tuncer C, Bu¨tu¨n V (2017)
pH-Responsive polymers. Polym Chem 8:
144–176
6. Lennox KA, Owczarzy R, Thomas DM,
Walder JA, Behlke MA (2013) Improved performance of anti-miRNA oligonucleotides
using a novel non-nucleotide modifier. Mol
Ther Nucleic Acids 2:e117
7. Makovitzki A, Fink A, Shai Y (2009) Suppression of human solid tumor growth inmice by
intratumor and systemic inoculation of
histidine-rich and pH-dependent host
defense–like lytic peptides. Cancer Res 69:
3458–3463
8. Yang C, Guo W, Cui L, Xiang D, Cai K,
Lin H, Qu F (2014) pH-responsive controlled-release system based on mesoporous
https://doi.org/10.
bioglass materials capped with mineralized
hydroxyapatite. Mater Sci Eng C 36:237 –243
9. Zhu L, Bratlie KM (2018) pH sensitive
methacrylated chitosan hydrogels with tunable physical and chemical properties. Biochem Eng J 132:38–46
10. Cicue´ndez M, Doadrio JC, Herna´ndez A,
Portole´s MT, Izquierdo-Barba I, Vallet-Regı
M (2018) Multifunctional pH sensitive 3D
scaffolds for treatment and prevention of
bone infection. Acta Biomater 65:450–461
11. Zhao C, Zeng Z, Qazvini NT, Yu X, Zhang R,
Yan S, Shu Y, Zhu Y, Duan C, Bishop E et al
(2018) Thermoresponsive citrate-based graphene oxide scaffold enhances bone regeneration from BMP9-stimulated adipose-derived
mesenchymal stem cells. ACS Biomater Sci
Eng 4:2943 –2955
12. Ye J, Wang J, Zhu Y, Wei Q, Wang X, Yang J,
Tang S, Liu H, Fan J, Zhang F et al (2016) A
thermoresponsive polydiolcitrate-gelatin scaffold and delivery system mediates effective
bone formation from BMP9-transduced mesenchymal stem cells. Biomed Mater 11:
025021
13. Slemming-Adamsen P, Song J, Dong M,
Besenbacher F, Chen M (2015) In situ
cross-linked PNIPAM/gelatin nanofibers for
thermo-responsive drug release. Macromol
Mater Eng 300:1226
14. Han S, Li M, Liu X, Gao H, Wu Y (2013)
Construction of amphiphilic copolymer nanoparticles based on gelatin as drug carriers for
doxorubicin delivery. Colloids Surf B Biointerfaces 102:833
15. Peng Y,
(2013) Optimization of thermosensitive chitosan hydrogels for the sustained delivery of
Li J, Li J, Fei Y, Dong J, Pan W
´

Stimuli-Responsive Drug Delivery Systems: From Concept to Clinical Translation 153
venlafaxine hydrochloride. Int J Pharm 441:
482–490
16. Li J, Zha Z, Ge Z (2016) Thermo-responsive
polyplex micelles with PEG shells and PNIPAM layer to protect DNA cores for systemic
gene therapy. In: Non-viral gene delivery vectors: methods and protocols, pp 269–276,
Humana Press,
17. Kesti M, Mu¨ ller M, Becher J,
Schnabelrauch M, D’Este M, Eglin D,
Zenobi-Wong M (2015) A versatile bioink
for three-dimensional printing of cellular scaffolds based on thermally and photo-triggered
tandem gelation. Acta Biomater 11:162–172
18. Mellati A, Fan CM, Tamayol A, Annabi N,
Dai S, Bi J et al (2017) Microengineered 3D
cell-laden thermoresponsive hydrogels for
mimicking cell morphology and orientation
in cartilage tissue engineering. Biotechnol
Bioeng 114(1):217–231
19. Jerca FA, Jerca V, Stancu I-C (2018) Development and characterization of photoresponsive polymers. In: Polymer and photonic
materials towards biomedical breakthroughs.
Springer International Publishing, Cham
20. Ercole F, Davis TP, Evans RA (2010) Photoresponsive systems and biomaterials: photochromic polymers, light-triggered self-assembly, surface modification, fluorescence
modulation and beyond. Polym Chem 1:37–
54
21. Wu S, Butt H-J (2016) Near-infrared-sensitive materials based on upconverting nanoparticles. Adv Mater 28:1208–1226
22. Ruskowitz ER, Deforest CA (2018) Photoresponsive biomaterials for targeted drug delivery and 4D cell culture. Nat Rev Mater 3:
17087–17104
23. Linsley CS, Wu BM (2017) Recent advances
in light-responsive on- demand drug-delivery
systems. Ther Deliv 8:89–107
24. Bandarab HMD, Burdette SC (2012) Photoisomerization in different classes of azobenzene. Chem Soc Rev 41:1809–1825
25. Udayabhaskararao T, Kundu PK, Ahrens J,
Klajn R (2015) Reversible photoisomerization of spiropyran on the surfaces of Au25
nanoclusters. ChemPhysChem 17:1805–
1809
26. Madaan K, Kumar S, Poonia N, Lather V,
Pandita D (2014) Dendrimers in drug delivery and targeting: drug-dendrimer interactions and toxicity issues. J Pharm Bioallied
Sci 6:139–150
27. Ahmad Z, Shah A, Siddiq M, Kraatz HB
(2014) Polymeric micelles as drug delivery
vehicles. RSC Adv 4:17028–17038
New York
28. Alavi M, Karimi N, Safaei M (2017) Application of various types of liposomes in drug
delivery systems. Adv Pharm Bull 7:3–9
29. Urban P, Pritzl SD, Konrad DB, Frank JA,
Pernpeintner C, Roeske CR, Trauner D, Lohmu¨ ller T (2018) Light-controlled lipid interaction and membrane organization in
photolipid bilayer vesicles. Langmuir 34:
13368–13374
30. Yao C, Wang P, Li X, Hu X, Hou J, Wang L,
Zhang F (2016) Near-infrared-triggered
azobenzene-liposome/upconversion nanoparticle hybrid vesicles for remotely controlled drug delivery to overcome cancer
multidrug resistance. Adv Mater 28:9341–
9348
31. Cui Z-K, Phoeung T, Rousseau P-A,
Rydzek G, Zhang Q, Bazuin CG, Lafleur M
(2014) Nonphospholipid fluid liposomes
with switchable photocontrolled release.
Langmuir 30:10818–10825
´
32. Kla
n P, Sˇolomek T, Bochet CG, Blanc A,
Givens R, Rubina M, Popik
Wirz J (2013) Photoremovable protecting
groups in chemistry and biology: reaction
mechanisms and efficacy. Chem Rev 113:
119 –191
33. Liu G, Dong C-MM (2012) Photoresponsive
Poly(S-(o-nitrobenzyl)-l-cysteine)-b-PEO
from a l-Cysteine N-Carboxyanhydride
Monomer: synthesis, self-assembly, and
phototriggered drug release. Biomacromolecules 13:1573–1583
34. Zhang D, Liu Z, Konetski D, Wang C, Worrell BT, Bowman CN (2018) Liposomes
formed from photo-cleavable phospholipids:
in situ formation and photo-induced
enhancement in per meability. RSC Adv 8:
14669–14675
35. Chandra B, Subramaniam R, Mallik S, Srivastava DK (2006) Formulation of photocleavable liposomes and the mechanism of their
content release. Org Biomol Chem 4:1730–
1740
36. Bayer AM, Alam S, Mattern-Schain SI, Best
MD (2014) Triggered liposomal release
through a synthetic phosphatidylcholine analogue bearing a photocleavable moiety
embedded within the sn-2 acyl chain. Chem
Eur J 20:3350–3357
37. Son S, Shin E, Kim BS (2014) Lightresponsive micelles of spiropyran initiated
hyperbranched polyglycerol for smart drug
delivery. Biomacromolecules 15:628–634
38. Petriashvili G,
Sepashvili N, Chubinidze K (2016) Light
controlled drug delivery containers based on
Devadze L, Zurabishvili T,
V, Kostikov
A,

154 Manisha et al.
spiropyran doped liquid crystal micro spheres.
Biomed Opt Express 7:442–446
39. Ou Y-C, Webb JA, Faley S, Shae D, Talbert
EM, Lin S, Cutright CC, Wilson JT, Bellan
LM, Bardhan R (2016) Gold nanoantennamediated photothermal drug delivery from
mosensitive liposomes in breast cancer.
ther
ACS Omega 1:234–243
40. Azagarsamy MA, McKinnon DD, Alge DL,
Anseth KS (2014) Coumarin-based photodegradable hydrogel: design, synthesis, gelation,
and degradation kinetics. ACS Macro Lett 3:
515–519
41. Hillel AT, Unterman S, Nahas Z, Reid B,
Coburn JM, Axelman J, Chae JJ, Guo Q,
Trow R, Thomas A et al (2011) Photoactivated composite biomaterial for soft tissue
restoration in rodents and in humans. Sci
Transl Med 3:93ra67
42. Zhang H, Patel A, Gaharwar AK, Mihaila SM,
Iviglia G, Mukundan S, Bae H, Yang H, Khademhosseini A (2013) Hyperbranched polyester hydrogels with controlled drug release
and cell adhesion properties. Biomacromolecules 14:1299–1310
43. Lee IN, Dobre O, Richards D, Ballestrem C,
Curran JM, Hunt JA, Richardson SM, Swift J,
Wong LS (2018) Photoresponsive hydrogels
with photoswitchable mechanical properties
allow time-resolved analysis of cellular
responses to matrix stiffening. ACS Appl
Mater Interfaces 10:7765–7776
44. Shin SR, Jung SM, Zalabany M, Kim K,
Zorlutuna P, Kim SB, Nikkhah M,
Khabiry M, Azize M, Kong J et al (2013)
Carbon-nanotube-embedded hydrogel sheets
for engineering cardiac constructs and bioactuators. ACS Nano 7:2369–2380
45. Kim O, Shin TJ, Park MJ (2013) Fast
low-voltage electroactive actuators using
nanostructured polymer electrolytes. Nat
Commun 4:2208
46. Vannozzi L, Ricotti L, Filippeschi C, Sartini S,
Coviello V, Piazza V, Pingue P, La Motta C,
Dario P, Menciassi A (2015) Nanostructured
ultra-thin patches for ultrasound-modulated
delivery of anti-restenotic drug. Int J Nanomedicine 11:69–92
47. Su Y, Hu Y, Du Y, Huang X, He J, You J,
Yuan H, Hu F (2015) Redox-responsive polymer-drug conjugates based on doxorubicin
and chitosan oligosaccharide- g -stearic acid
for cancer therapy. Mol Pharm 12:1193–
1202
48. Nehate C, Nayal A, Koul V (2018) Redox
responsive polymersomes for enhanced doxorubicin delivery. ACS Biomater Sci Eng 2:
511–517
49. Li Q, Yang S, Zhu L, Kang H, Qu X, Liu R,
Huang Y (2015) Dual-stimuli sensitive keratin graft PHPMA as physiological trigger
responsive drug carriers. Polym Chem 6:
2869–2878
50. Hoop M, Chen XZ, Ferrari A, Mushtaq F,
Ghazaryan G, Tervoort T, Poulikakos D,
Nelson B, Pane´ S (2017) Ultrasoundmediated piezoelectric differentiation of
neuron-like PC12 cells on PVDF membranes.
Sci Rep 7:4028–4036
51. Baumgartner J, Jo¨nsson JI, Jager EWH
(2018) Switchable presentation of cytokines
on electroactive polypyrrole surfaces for
hematopoietic stem and progenitor cells. J
Mater Chem B 6:4665–4675
52. Abu-Dief AM, Abdel-Fatah SM (2018)
Development and functionalization of magnetic nanoparticles as powerful and green catalysts for organic synthesis. Beni-Suef Univ J
Basic Appl Sci 7:55–67
53. Kayode B, Abdul A (2016) Recent advances in
synthesis and surface modi fi cation of superparamagnetic iron oxide nanoparticles with
silica. J Magn Magn Mater 416:275–291
54. Teixeira SD, de Mendonc¸a E, Britto de Faria
AC, Loureiro Dias SC, Arago´n FFH, Mantilla
JC, Coaquira JAH, Dias JA (2018) Effects of
silica coating on the magnetic properties of
magnetite nanoparticles. Surfaces Interfaces
14:34–
43
55. Zhang Y, Zhen B, Li H, Feng Y (2018) Preparation of water-soluble magnetic nanoparticles with controllable silica coating. Chinese J
Chem Eng 26:213–217
56. Bui TQ, Ngo HTM, Tran HT (2018)
Surface-protective assistance of ultrasound in
synthesis of superparamagnetic magnetite
nanoparticles and in preparation of monocore magnetite-silica nanocomposites. J Sci
Adv Mater Devices 3:323–330
57. Chen Z, Wu C, Zhang Z, Wu W, Wang X, Yu
Z (2018) Synthesis, functionalization, and
nanomedical applications of functional magnetic nanoparticles. Chinese Chem Lett 29:
1601–1608
58. Teixeira SD, de Mendonc¸a E, Britto de Faria
AC, Loureiro Dias SC, Arago
JC, Coaquira JAH, Dias JA (2018) Effects of
silica coating on the magnetic properties of
magnetite nanoparticles. Surf Interfaces 14:
34–43
59. Laurent S, Forge D, Port M, Roch A,
Robic C, Elst LV, Muller RN (2008) Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical
characterizations, and biological applications.
Chem Rev 108:2064–2110
´
n FFH, Mantilla

Stimuli-Responsive Drug Delivery Systems: From Concept to Clinical Translation 155
60. Gul S, Khan SB, Rehman IU, Khan MA, Khan
MI (2019) A comprehensive review of magnetic nanomaterials modern day theranostics.
Front Mater 6:179
61. Frey NA, Peng S, Cheng K, Sun S (2009)
Magnetic nanoparticles: synthesis, functionalization, and applications in bioimaging and
magnetic energy storage. Chem Soc Rev 38:
2532–2542
62. Schmid G, Fenske D (2010)
and nanoparticles. Philos Trans R Soc A
Math Phys Eng Sci 368:1207–1210
63. Neoh KG, Kang ET (2012) Surface modification of magnetic nanoparticles for stem cell
labeling. Soft Matter 8:2057–2069
64. Thong-On B, Rutnakornpituk B, Wichai U,
Rutnakornpituk M (2012) Magnetite nanoparticle coated with amphiphilic bilayer surfactant of polysiloxane and poly(poly(ethylene
glycol) methacrylate). J Nanopart Res 14:
953–965
65. Rao KM, Kumar A, Han SS (2018)
Polysaccharide-based magnetically responsive
polyelectrolyte hydrogels for tissue engineering applications. J Mater Sci Technol 34:
1371–1377
66. Municoy S, Iban˜ez IL, Dura´n H, Bellino MG
(2014) A catalase-magnetic switch for cell
proliferation. RSC Adv 4:15077
67. Yang HM, Park CW, Park S, Kim JD (2018)
Cross-linked magnetic nanoparticles with a
biocompatible amide bond for cancertargeted dual optical/magnetic resonance
imaging. Colloids Surf B Biointerfaces 161:
183–191. [CrossRef] [PubMed]
68. Ito A, Kamihira M (2011) Tissue engineering
using magnetite nanoparticles. Prog Mol Biol
Transl Sci 104:355–395
69. Rotherham M, Henstock JR, Qutachi O, El
Haj AJ (2018) Remote regulation of magnetic
particle targeted Wnt signaling for bone tissue
engineering. Nanomed Nanotechnol Biol
Med 14:173–184
70. Svirskis D, Travas-Sejdic J, Rodgers A, Garg S
(2010) electrochemically controlled drug
delivery based on intrinsically conducting
polymers. J Control Release 146:6–1
71. Murdan S (2003) Electro-responsive drug
delivery from hydrogels. J Control Release
92:1–17
72. Ying X, Wang Y, Liang J, Yue J, Xu C, Lu L,
Xu Z, Gao J, Du Y, Chen Z (2014) Angiopepconjugated electro-responsive hydrogel nanoparticles: therapeutic potential for epilepsy.
Angew Chem Int Ed 53:12436–12440
73. Lira LM, Co´rdoba de Torresi SI (2008) Polymeric electro-mechanic devices applied to
Metal clusters
antibiotic-controlled release. Sensors Actuators B Chem 130:638–644
74. Kumar S, Allard J-F, Morris D, Dory YL,
Lepage M, Zhao Y (2012) Near-infrared
light sensitive polypeptide block copolymer
micelles for drug delivery. J Mater Chem 22:
7252–7257
75. Liu J, Ong W, Roma´n E, Lynn MJ, Kaifer AE
(2000) Cyclodextrin-modified gold nanospheres. Langmuir 16:3000– 3002
76. Park C, Youn H, Kim H, Noh T, Kook YH,
Oh ET, Park HJ, Kim C (2009) Cyclodextrin
covered gold nanoparticles for targeted delivery of an anti-cancer drug. J Mater Chem 19:
2310–2315
77. Sun I-C, Lee S, Koo H, Kwon IC, Choi K,
Ahn C-H, Kim K (2010) Caspase sensitive
gold nanoparticle for apoptosis imaging in
live cells. Bioconjug Chem 21:1939–1942
78. Schubert S, Delaney JJT, Schubert US (2011)
Nanoprecipitation and nanoformulation of
polymers: from history to powerful possibilities beyond poly(lactic acid). Soft Matter 7:
1581–1588
79. Sun H, Guo B, Cheng R, Meng F, Liu H,
Zhong Z (2009) Biodegradable micelles with
sheddable poly(ethylene glycol) shells for triggered intracellular release of doxorubicin.
Biomaterials 30:6358–6366
80. Luo Z, Cai K, Hu Y, Zhao L, Liu P, Duan L,
Yang W (2011) Mesoporous silica nanoparticles end-capped with collagen: redoxresponsive nanoreservoirs for targeted drug
delivery. Angew Chem Int Ed 50:640–643
81. Qiu Y, Park K (2001) Environment-sensitive
hydrogels for drug delivery. Adv Drug Deliv
Rev 53:321–339
82. Guerin M, Huntley ME, Olaizola M (2003)
Haematococcus astaxanthin: applications for
human health and nutrition. Trends Biotechnol 21:210–216
83. Yavuz MS, Cheng Y, Chen J, Cobley CM,
Zhang Q, Rycenga M, Xie J, Kim C, Song
KH, Schwartz AG, Wang LV, Xia Y (2009)
Gold nanocages covered by smart polymers
for controlled release with near-infrared
light. Nat Mater 8:935
84. Agostinis P, Berg K, Cengel KA, Foster TH,
Girotti AW, Gollnick SO, Hahn SM, Hamblin
MR, Juzeniene A, Kessel D, Korbelik M,
Moan J, Mroz P, Nowis D, Piette J, Wilson
BC, Golab J (2011) Photodynamic therapy of
cancer: an update. CA Cancer J Clin 61:250–
281
85. Madhusudana Rao
CS (2018) Functional stimuli-responsive
polymeric network nanogels as cargo systems
K, Krishna Rao KSV, Ha

156 Manisha et al.
for targeted drug delivery and gene delivery in
cancer cells. In: Andrew W (ed) Design of
nanostructures for theranostics applications.
Elsevier, pp 243–275
86. Gallo J, Long NJ, Aboagye EO (2013) Magnetic nanoparticles as contrast agents in the
diagnosis and treatment of cancer. Chem Soc
Rev 42:7816–7833
87. Neuberger T, Scho¨pf B,
Hofmann M, Von Rechenberg B (2005)
Superparamagnetic nanoparticles for biomedical applications: possibilities and limitations
of a new drug delivery system. J Magn Magn
Mater 293:483–496
88. Santhosh PB, Ulrih NP (2013) Multifunctional superparamagnetic iron oxide nanoparticles: promising tools in cancer theranostics.
Cancer Lett 336:8–17
89. Acar HY, Garaas RS, Syud F, Bonitatebus P,
Kulkarni AM (2005) Superparamagnetic
nanoparticles stabilized by polymerized
PEGylated coatings. J Magn Magn Mater
293:1–7
90. Guisasola E, Baeza A, Talelli M, Arcos D,
Moros M, de la Fuente JSM, ValletRegı´ M
(2015) Magnetic-responsive release controlled by hot spot effect. Langmuir 31:
12777–12782
91. Teleki A, Haufe FL, Hirt AM, Pratsinis SE,
Sotiriou GA (2016) Highly scalable production of uniformly-coated superparamagnetic
nanoparticles for triggered drug release from
alginate hydrogels. RSC Adv 6:21503–21510
92. Harris M, Ahmed H, Barr B, LeVine D,
Pace L, Mohapatra A, Morshed B, Bumgardner JD, Jennings JA (2017) Magnetic stimuliresponsive chitosan-based drug delivery biocomposite for multiple triggered release. Int J
Biol Macromol 104:1407–1414
93. Hassouneh W, MacEwan SR, Chilkoti A
(2012) Fusions of elastin-like polypeptides to
pharmaceutical proteins. Methods Enzymol
502:215–237
94. Banchelli M, Nappini S, Montis C, Bonini M,
Canton P, Berti D, Baglioni P (2014) Magnetic nanoparticle clusters as actuators of
ssDNA release. Phys Chem Chem Phys 16:
10023–10031
95. Silva AK, Kolosnjaj-Tabi J, Bonneau S,
Marangon I, Boggetto N, Aubertin K,
´
Cle
ment O, Bureau MF, Luciani N, Gazeau
F (2013) Magnetic and photoresponsive theranosomes: translating cell-released vesicles
into smart nanovectors for cancer therapy.
ACS Nano 7:4954–4966
96. N’Guyen TT, Duong HT, Basuki J,
Montembault V, Pascual S, Guibert C,
Hofmann H,
Fresnais J, Boyer C, Whittaker MR, Davis
TP (2013) Functional
nanoparticles with hyperthermia-induced
drug release ability by using a combination
of orthogonal click reactions. Angew Chem
Int Ed 52:14152–14156
97. Hansen MJ, Velema WA, Lerch MM,
Szymanski W, Feringa BL (2015) Wavelengthselective cleavage of photoprotecting
groups: strategies and applications in dynamic
systems. Chem Soc Rev 44:3358–3377
98. Jin Q, Mitschang F, Agarwal S (2011) Biocompatible drug delivery system for phototriggered controlled release of 5-fluorouracil.
Biomacromolecules 12:3684–3691
99. Bandara HD, Burdette SC (2012) Photoisomerization in different classes of azobenzene. Chem Soc Rev 41:1809–1825
100. Geng S, Wang Y, Wang L, Kouyama T,
Gotoh T, Wada S, Wang J-Y (2017) A lightresponsive self-assembly formed by a cationic
azobenzene derivative and SDS as a drug
delivery system. Sci Rep 7:39202
101. Rwei AY, Lee J-J, Zhan C, Liu Q, Ok MT,
Shankarappa SA, Langer R, Kohane DS
(2015) Repeatable and adjustable
on-demand sciatic nerve block with phototriggerable liposomes. Proc Natl Acad Sci
112:15719–
102. Pashkovskaya A, Kotova E, Zorlu Y,
Dumoulin F, Ahsen V, Agapov I, Antonenko
Y (2009) Light-triggered liposomal release:
membrane permeabilization by photodynamic action. Langmuir 26:5726–5733
103. Luo D, Li N, Carter KA, Lin C, Geng J,
Shao S, Huang WC, Qin Y, Atilla- Gokcumen
GE, Lovell JF (2016) Rapid light-triggered
drug release in liposomes containing small
amounts of unsaturated and porphyrin–phospholipids. Small 12:3039–3047
104. Kwon IC, Bae YH, Kim SW (1994) Heparin
release from polymer complex. J Control
Release 30:155–159
105. Dutta K, Kundu PP (2013) Reversible assembly and disassembly of amphiphilic assemblies
by electropolymerized polyaniline films:
effects rendered by varying the electropolymerization potential. J Phys Chem B 117:
7797–7805
106. MacDonald RA,
gemann JP (2008) Carbon nanotubes
increase the electrical conductivity of
fibroblast-seeded collagen hydrogels. Acta
Biomater 4:1583–1592
107. Voge
Stegemann JP (2013) Wrapping and dispersion of multiwalled carbon nanotubes
15724
CM, Johns J, Raghavan M, Morris MD,
iron oxide
CM, Kariolis M, Ste-
Voge
magnetic

Stimuli-Responsive Drug Delivery Systems: From Concept to Clinical Translation 157
improves electrical conductivity of protein–
nanotube composite
Mater Res A 101:231–238
108. Yang J, Choe G, Yang S, Jo H, Lee JY (2016)
Polypyrrole-incorporated conductive hyaluronic acid hydrogels. Biomater Res 20:31
109. Mac Kenna N, Calvert P, Morrin A, Wallace
GG, Moulton SE (2015) Electro-stimulated
release from a reduced graphene oxide composite hydrogel. J Mater Chem B 3:2530–
2537
110. Lee MR, Baek KH, Jin HJ, Jung YG, Shin I
(2004) Targeted enzyme-responsive drug
carriers: studies on the delivery of a
biomaterials. J Biomed
combination of drugs. Angew Chem Int Ed
43:1675–1678
111. Wong C, Stylianopoulos T, Cui J, Martin J,
Chauhan VP, Jiang W, Popovic´ Z, Jain RK,
Bawendi MG, Fukumura D (2011) Multistage nanoparticle delivery system for deep
penetration into tumor tissue. Proc Natl
Acad Sci 108:2426–2431
112. Wan
Y, Han J, Fan G, Zhang Z, Gong T, Sun
X (2013) Enzyme-responsive liposomes modified adenoviral vectors for enhanced tumor
cell transduction and reduced immunogenicity. Biomaterials 34:3020–3030

Соседние файлы в папке Библиотека им академика М.И. Перельмана
